Abstract
Mesangial proliferative glomerulonephritis (MsPGN), the most common pathological change in primary glomerulonephritis, is characterized by increased macrophage infiltration into glomeruli, which results in proinflammatory cytokine release. Macrophage infiltration and differentiation are induced by the Janus kinase 2 and signal transducer and activator of the transcription 1 (JAK2/STAT1) pathway. As a suppressor of cytokine signaling 1 (SOCS1) downregulates the immune response by inhibiting the JAK2/STAT1 pathway, we investigated whether a peptide mimicking the SOCS1 kinase inhibitor region, namely, SOCS1 peptidomimetic, protects against nephropathy. Glomerular JAK2/STAT1 pathway activation was synchronized with kidney injury in an MsPGN rat model. Rats treated with the SOCS1 peptidomimetic exhibited reduced pathological glomerular changes and lessened macrophage recruitment. Moreover, in vivo, the phosphorylation of the JAK2/STAT1 pathway was downregulated in infiltrated macrophages of glomeruli. In vitro, the SOCS1 peptidomimetic inhibited macrophage M1 polarization by suppressing JAK2/STAT1 activation. In conclusion, our study demonstrated that the SOCS1 peptidomimetic plays a protective role against pathologic glomerular changes in MsPGN by reducing macrophage infiltration and inhibiting macrophage polarizing to the M1 phenotype. SOCS1 peptidomimetic, therefore, presents a feasible therapeutic strategy to alleviate renal inflammation in MsPGN.
Similar content being viewed by others
Availability of Data and Materials
The data and materials are available when requested.
Change history
06 September 2023
A Correction to this paper has been published: https://doi.org/10.1007/s10753-023-01899-y
References
Jin, M., Z. Yin, K. Wei, et al. 2019. Metanephric mesenchyme-derived Foxd1 mesangial precursor cells alleviate mesangial proliferative glomerulonephritis[J]. Journal of molecular medicine (Berlin, Germany) 97 (4): 553–561.
Lu, Y., Y. Mei, L. Chen, et al. 2019. The role of transcriptional factor D-site-binding protein in circadian CCL2 gene expression in anti-Thy1 nephritis[J]. Cellular & molecular immunology 16 (9): 735–745.
Ikezumi, Y., T. Suzuki, T. Karasawa, et al. 2010. Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis[J]. American journal of nephrology 31 (3): 273–282.
Yoshimura, A., K. Inui, T. Nemoto, et al. 1998. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis[J]. Journal of the American Society of Nephrology : JASN 9 (11): 2027–2039.
Shapouri-Moghaddam, A., S. Mohammadian, H. Vazini, et al. 2018. Macrophage plasticity, polarization, and function in health and disease[J]. Journal of cellular physiology 233 (9): 6425–6440.
Wang, L.-X., S.-X. Zhang, H.-J. Wu, et al. 2019. M2b macrophage polarization and its roles in diseases[J]. Journal of leukocyte biology 106 (2): 345–358.
Hata, Y., T. Kuwabara, K. Mori, et al. 2020. Ablation of myeloid cell MRP8 ameliorates nephrotoxic serum-induced glomerulonephritis by affecting macrophage characterization through intraglomerular crosstalk[J]. Scientific reports 10 (1): 3056.
Liao, W.-Q., S.-Y. Cui, Q. Ouyang, et al. 2018. Modulation of macrophage polarization by human glomerular mesangial cells in response to the stimuli in renal microenvironment[J]. Journal of Interferon & Cytokine Research : The Official Journal of the International Society For Interferon and Cytokine Research 38 (12): 566–577.
Sica, A., and A. Mantovani. 2012. Macrophage plasticity and polarization: In vivo veritas[J]. The Journal of clinical investigation 122 (3): 787–795.
Ikezumi, Y., L.A. Hurst, T. Masaki, et al. 2003. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation[J]. Kidney international 63 (1): 83–95.
Rampino, T., G. Soccio, M. Gregorini, et al. 2007. Neutralization of macrophage-stimulating protein ameliorates renal injury in anti-thy 1 glomerulonephritis[J]. Journal of the American Society of Nephrology : JASN 18 (5): 1486–1496.
Hu, J., X. Fan, X. Meng, et al. 2014. Evidence for the involvement of JAK/STAT/SOCS pathway in the mechanism of Tangshen formula-treated diabetic nephropathy[J]. Planta medica 80 (8–9): 614–621.
Brosius, F.C., and J.C. He. 2015. JAK inhibition and progressive kidney disease[J]. Current opinion in nephrology and hypertension 24 (1): 88–95.
Owen, K.L., N.K. Brockwell, and B.S. Parker. 2019. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression[J]. Cancers 11 (12).
Butturini, E., D. Boriero, A. Carcereri De Prati, et al. 2019. STAT1 drives M1 microglia activation and neuroinflammation under hypoxia[J]. Archives of biochemistry and biophysics 669: 22–30.
Liu, Y., Z. Liu, H. Tang, et al. 2019. The -methyladenosine (mA)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of mRNA[J]. American journal of physiology Cell physiology 317 (4): C762–C775.
Gan, Z.-S., Q.-Q. Wang, J.-H. Li, et al. 2017. Iron Reduces M1 Macrophage polarization in RAW264.7 macrophages associated with inhibition of STAT1[J]. Mediators of inflammation 2017: 8570818.
Wang, F., S. Zhang, R. Jeon, et al. 2018. Interferon gamma induces reversible metabolic reprogramming of M1 macrophages to sustain cell viability and pro-inflammatory activity[J]. eBioMedicine 30: 303–316.
Ding, N., Y. Wang, C. Dou, et al. 2019. Physalin D regulates macrophage M1/M2 polarization via the STAT1/6 pathway[J]. Journal of cellular physiology 234 (6): 8788–8796.
Durham, G.A., J.J.L. Williams, M.T. Nasim, et al. 2019. Targeting SOCS Proteins to control JAK-STAT signalling in disease[J]. Trends in pharmacological sciences 40 (5): 298–308.
Yoshimura, A., M. Ito, S. Chikuma, et al. 2018. Negative regulation of cytokine signaling in immunity[J]. Cold Spring Harbor perspectives in biology 10 (7).
Sharma, J., T.D. Collins, T. Roach, et al. 2021. Suppressor of cytokine signaling-1 mimetic peptides attenuate lymphocyte activation in the MRL/lpr mouse autoimmune model[J]. Scientific reports 11 (1): 6354.
Bernal, S., L. Lopez-Sanz, L. Jimenez-Castilla, et al. 2021. Protective effect of suppressor of cytokine signalling 1-based therapy in experimental abdominal aortic aneurysm[J]. British Journal of Pharmacology 178 (3): 564–581.
Plummer, C.E., T. Polk, J. Sharma, et al. 2022. Open label safety and efficacy pilot to study mitigation of equine recurrent uveitis through topical suppressor of cytokine signaling-1 mimetic peptide[J]. Scientific reports 12 (1): 7177.
Liu, B., J. Lin, L. Bai, et al. 2019. Paeoniflorin inhibits mesangial cell proliferation and inflammatory response in rats with mesangial proliferative glomerulonephritis through PI3K/AKT/GSK-3β pathway[J]. Frontiers in pharmacology 10: 978.
Bai, J., L. Wu, X. Chen, et al. 1982. Suppressor of cytokine signaling-1/STAT1 regulates renal inflammation in mesangial proliferative glomerulonephritis models[J]. Frontiers in immunology 2018: 9.
Linossi, E.M., J.J. Babon, D.J. Hilton, et al. 2013. Suppression of cytokine signaling: The SOCS perspective[J]. Cytokine & growth factor reviews 24 (3): 241–248.
Liang, Y.-B., H. Tang, Z.-B. Chen, et al. 2017. Downregulated SOCS1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type[J]. Molecular medicine reports 16 (5): 6405–6411.
Lopez-Sanz, L., S. Bernal, C. Recio, et al. 2018. SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition[J]. Laboratory investigation; a journal of technical methods and pathology 98 (10): 1276–1290.
He, C., C.-R. Yu, M.J. Mattapallil, et al. 2016. SOCS1 mimetic peptide suppresses chronic intraocular inflammatory disease (Uveitis)[J]. Mediators of inflammation 2016: 2939370.
La Manna, S., L. Lopez-Sanz, S. Bernal, et al. 2020. Antioxidant effects of PS5, a peptidomimetic of suppressor of cytokine signaling 1, in experimental atherosclerosis[J]. Antioxidants (Basel, Switzerland) 9 (8).
Madonna, S., C. Scarponi, N. Doti, et al. 2013. Therapeutical potential of a peptide mimicking the SOCS1 kinase inhibitory region in skin immune responses[J]. European journal of immunology 43 (7): 1883–1895.
Author information
Authors and Affiliations
Contributions
Yinghua Zhao wrote the main manuscript text. Fei Peng and Lingling Wu edited the main manuscript text. Jiayi He, Huiming Ni, and Yilun Qu validated the experiments. Xiangmei Chen provided project administration. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original online version of this article was revised: The email address of the second corresponding author was not captured in the published version and it should be, wulingling19860328@163.com.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhao, Y., Peng, F., He, J. et al. SOCS1 Peptidomimetic Alleviates Glomerular Inflammation in MsPGN by Inhibiting Macrophage M1 Polarization. Inflammation 46, 2402–2414 (2023). https://doi.org/10.1007/s10753-023-01886-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-023-01886-3